EyePoint Pharmaceuticals

Press Releases

pSivida Reports ILUVIEN® Granted Marketing Authorization in Ireland
Nov 17, 2014
Now Approved in 13 Countries Worldwide WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the Irish Health Products Regulatory Authority (HPRA) has
pSivida Reports ILUVIEN® Granted Marketing Authorization in Belgium
Nov 12, 2014
Now Approved in 12 Countries Worldwide WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the Belgian Federal Agency for Medicines and Health Products
pSivida Corp. Reports First Quarter FY 2015 Results
Nov 07, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its first quarter ended September 30, 2014 .
pSivida Corp. Announces First Quarter Fiscal 2015 Financial Results Release Date and Conference Call Information
Oct 31, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the first quarter of fiscal year 2015 will be released before the market
pSivida Corp. Receives $25 Million Milestone Payment
Oct 27, 2014
Planned Operations Funded into 2017 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV, ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that it has received the $25 million milestone payment under its
pSivida Corp. Reports FDA Approval of ILUVIEN® for Diabetic Macular Edema
Sep 26, 2014
pSivida earns $25 million milestone WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved ILUVIEN®
pSivida Corp. Names James Barry to Board of Directors
Sep 10, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that it has elected James J. Barry, Ph.D. to its Board of Directors. Dr.
pSivida Corp. Reports Fourth Quarter and FY 2014 Results
Sep 09, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its fourth quarter and fiscal year ended June 30, 2014 .
pSivida Corp Announces Fourth Quarter and Fiscal Year 2014 Financial Results Release Date and Conference Call Information
Sep 03, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the fourth quarter and fiscal year 2014 will be released after the market
pSivida Corp. Reports ILUVIEN® for Chronic Diabetic Macular Edema Receives Marketing Authorization in Sweden, 10th EU Approval
Sep 03, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Swedish Medical Products Agency granted marketing authorization to ILUVIEN® for the treatment of
pSivida Corp. Reports ILUVIEN® for Chronic Diabetic Macular Edema Receives Marketing Authorization in Denmark, 9th EU Approval
Jul 31, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Danish Health and Medicines Authority granted marketing authorization to ILUVIEN® for the
pSivida Announces ILUVIEN® Receives Marketing Authorization in Norway and Approval for Reimbursement in Portugal
Jul 28, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that ILUVIEN® has been has granted marketing authorization in Norway for the treatment of vision
pSivida Corp. Reports Positive Regulatory Outcome for ILUVIEN®; Moves to National Phase for Marketing Authorizations in 10 More EU Countries
Jun 30, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the regulatory process for marketing authorizations in Belgium , the Czech Republic , Denmark ,
pSivida Announces ILUVIEN® Receives Marketing Authorization in Italy for Treatment of Chronic Diabetic Macular Edema
Jun 23, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to
pSivida Corp. Reports Third Quarter 2014 Results
May 13, 2014
Now Plans to Seek US approval of Medidur for Posterior Uveitis Based on One Phase III Trial WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial
pSivida Presents Preclinical Data Demonstrating Sustained Release of Avastin Using Tethadur at ARVO Annual Meeting
May 05, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that the Company presented the first peer-reviewed preclinical data demonstrating the use of pSivida's Tethadur™
pSivida Corp Announces Third Quarter 2014 Financial Results Release Date and Conference Call Information
May 02, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year 2014 will be released after the market
pSivida Reports Australia/New Zealand Distribution Agreement for ILUVIEN® for DME
Apr 28, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has signed an exclusive agreement with Specialised Therapeutics
pSivida Selected to Present at 2014 Opthalmology Innovation Summit
Apr 23, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that pSivida has been selected for the Ophthalmic Companies Showcase at The Ophthalmology Innovation Summit (OIS), April
pSivida Announces September 26, 2014 PDUFA Date for ILUVIEN®
Apr 14, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA)
Displaying 121 - 140 of 326
EyePoint Pharmaceuticals